Regeneron Pasatru Phase 3 Results: No New FOP Lesions
Regeneron Pasatru Phase 3 results: no new FOP bone lesions from weeks 56 to 84 versus nine on placebo. Already approved; infections rose with dose.
Regeneron Pasatru Phase 3 results: no new FOP bone lesions from weeks 56 to 84 versus nine on placebo. Already approved; infections rose with dose.